1. Introduction {#s0005}
===============

A virus is an infectious entity that needs, for reproducing, a host cell in a living organism. Viruses constitute a ubiquitous biological entity on our planet \[[@bb0005]\]. Coronavirus disease 2019 (COVID-19) is caused by the new SARS-CoV-2 \[[@bb0010]\]. WHO report published on 4th of June 2020 (Situation Report-136) shows that there are 3,416,828 confirmed cases worldwide \[[@bb0015]\]. Since WHO-81 report from 10 April, the number of cases rise accelerated from 92,798 deaths to 157,847 on 20 April \[[@bb0015],[@bb0020]\]. The massive number of persons infected by SARS-CoV-2 demands new, more potent treatments.

Drug repositioning is a viable approach instead of developing new drugs in the context of new infectious diseases; this leads to compounds that are de-risked and have lower development costs \[[@bb0025]\]. In silico studies are a good alternative in an emergent situation to repose a chemical compound \[[@bb0030]\]. Molecular docking approach is a fast, low-cost procedure used to predict at molecular level the interaction between a ligand and a target \[[@bb0035]\].

Phenothiazines are chemicals with high antipathogen proprieties against pathogens such as: (i) Protozoa *Plasmodium falciparum* (protozoan responsible for malaria) \[[@bb0040]\], genus Leishmania (that cause Leishmaniasis) \[[@bb0045]\], (ii) several resistant bacterial strains (Multidrug-resistant *Mycobacterium tuberculosis* and Methicillin-resistant *Staphylococcus aureus*) and (iii) viruses such as those responsible for hepatitis B, HIV, TBEV, arenavirus, herpesvirus etc. \[[@bb0045]\]. Moreover, in previous epidemies with SARS-CoV-1 and MERS viruses, chlorpromazine (CPZ) shows high inhibitory activity and was recommended as a candidate for testes as a broad-spectrum antiviral \[[@bb0050]\]. Here, our aim is to propose the antiviral role of phenothiazines against COVID-19.

Phenothiazines like Thioridazine (TZ) and CPZ generate, by exposure to laser radiation, photoproducts that are more efficient in inhibition of bacterial strains than non-irradiated drugs \[[@bb0055]\].

To find the mechanism of action of TZ after irradiation, we have identified the generated photoproducts. In a previous study, TZ was irradiated up to 11 min with 355 nm Nd:YAG pulsed laser beam which has full-time width at half maximum 5 ns and the average pulse energy on the sample 30 mJ at a repetition rate of 10 pps. Using chromatographic methods (HPLC-MS) we have identified two TZ photoproducts: mesoridazine (MSO) and sulphoridazine (SPZ), those photoproducts are as well TZ metabolites. Molecular structure modifications occur through preferential oxidation in (-SCH3) radical zone \[[@bb0060]\].

CPZ photoproducts were obtained after irradiation with an Nd:YAG pulsed laser beam at 266 nm with an average pulse energy of 6.5 mJ. The CPZ samples at 2 mg/mL in ultrapure water irradiated 1, 5, 15, 30, 60, 120,180 and 240 min were analysed using LC-TOF/MS. Results showed seven CPZ generated photoproducts: promazine (PZ), P1, P2, 2-hydroxypromazinesulfoxide (2-HO-PZ-SO), chlorpromazine sulfoxide (CPZ-SO), promazine sulfoxide (PZ-SO) and 2-hidroxipromazine (2-HO-PZ) \[[@bb0065]\]. We mention that the photoproducts MSO and SPZ may also be used as antipsychotics.

The replications of coronaviruses are blocked by inhibiting the protease of the virus \[[@bb0070]\]. For identifying a treatment of COVID-19 disease, we used molecular docking procedure to predict the inhibitory activity (against SARS-CoV-2) M^pro^ of some compounds from phenothiazines drug class. This study also predicts the binding affinity of TZ and CPZ known photoproducts generated by laser irradiation with the M^pro^.

2. Materials and Methods {#s0010}
========================

2.1. Identify the Viral Protease {#s0015}
--------------------------------

To simulate the interaction between SARS-CoV-2 and drugs from the class of phenothiazines including TZ and CPZ photoproducts we have used the virus M^pro^ from RCSB Protein Data Bank: PDB code [6LU7](pdb:6LU7){#ir0015} \[[@bb0075]\]. The structure of the enzyme was obtained using X-ray diffraction at a resolution of 2.16 Å \[[@bb0075]\]. We have chosen the M^pro^ of the virus due to the essential role of this enzyme in proteolytic maturation of the nonstructural proteins. This enzyme represents a potential target in the development of antiviral drugs \[[@bb0080]\].

2.2. Molecular Docking Protocol {#s0020}
-------------------------------

We have prepared the molecule for docking studies by deleting water, adding hydrogen, merging the non-polar hydrogen and adding Gasteiger partial charges \[[@bb0085]\]. The small molecules were drawn and optimized geometrically using Discovery studio visualizer. After optimization, we have saved the molecules in .mol format \[[@bb0090]\]. After geometrical optimization, we have used OpenBabel software \[[@bb0095]\] to shape the molecule in .pdbqt format. For molecular docking approach, we have used Autodock 4.2.6 software \[[@bb0100]\].

Grid-box was selected to contain only the protease situs identified by amino acids: His 41, Met 49, Phe 140, Asn142 Gly 143, Cys 145, His 163, His 164, Glu 166 and His 172 \[[@bb0105],[@bb0110]\]. Covalent grid parameters had an energy barrier height of 1000 and the half-width of 5.00 Å. Total grid Pts per map is 257,725. The grid has the number of points in dimensions: x-60; y-64 and z-64 and the cartesian coordinates of central grid point of maps were set to x = −11.86, y = 17.38, z = 68.99. The spacing of grid points was set to 0.375 Å. For docking simulation, we generated 100 conformations for each ligand; the used search parameter to identify the binding conformation of the ligands was Genetic Algorithm and the output was saved as Lamarckian.

3. Results and Discussions {#s0025}
==========================

Generally, a molecular docking result is represented by Estimated Free Energy of Binding (EFEB). Higher biological activity of a drug is correlated with lower free energy of binding \[[@bb0115], [@bb0120], [@bb0125]\]. Here, EFEB was calculated as EFEB = (1) + (2) + (3)--(4) using Autodock 4.2.6 software where:(1)is Final Intermolecular Energy vdW + H-bond + desolv Energy Electrostatic Energy.(2)represents Final Total Internal Energy.(3)is Torsional Free Energy.(4)represents unbound System\'s Energy \[=(2)\].

Furthermore, the estimated inhibition constant K~I~ was predicted by Autodock 4.2.6 at 298.15 K; a lower K~I~ is correlated with high biological activity (pK~I~) \[[@bb0130]\]. For improved data analysis, we converted K~I~ values (nM) in pK~I~ by applying the logarithm function: *pKi* = *log* (1/*Ki*(*M*)). A pK~I~ value of 4 or lower will define a compound with no biological activity.

TZ presents an estimated Inhibition Constant (Ki) of 244.97 nM ([Table 1](#t0005){ref-type="table"} ), this energy being lower than EFEB of remdesivir (−7.80 kcal/mol) which is predicted with autodockVina \[[@bb0110]\].Table 1The 2D/3D chemical structure of compounds from Phenothiazines class and TZ and CPZ photoproducts that resulted during laser irradiation; 2D chemical structure, lowest EFEB (kcal/mol) for each compound resulted after 100 runs using molecular docking simulation, predicted KI (nM) and pKI values are also presented. PZ -- the acronym of promazine.Table 1

We have compared our results with remdesivir antiviral drug due to improvements showed in patients infected with SARS-CoV-2 \[[@bb0135]\]; moreover, remdesivir interacts with the enzyme in the main situs of interaction \[[@bb0110]\], same as MSO ([Fig. 1](#f0005){ref-type="fig"} ).Fig. 13D image of SPZ in the interaction situs of SARS-CoV-2 M^pro^ (PDB: [6LU7](pdb:6LU7){#ir0005}) \[[@bb0075]\]. Dotted with red, amino acids from the binding situs of the protease \[[@bb0105],[@bb0110]\] situated in close contact at a VDW scaling factor closer than 1. Dotted green line underlines an h-bond interaction between SPZ and His163. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 1

Photoproducts resulted after laser irradiation of TZ present higher biological activities than TZ (Table1).

From [Table 1](#t0005){ref-type="table"} it results that SPZ presents the highest biological activity on SARS-CoV-2 M^pro^ (pKI = 7.42) and it is in close contact with SARS-CoV-2 amino acids residues from the situs of interaction ([Fig. 1](#f0005){ref-type="fig"}).

For a compound with no activity we have used as threshold an EFEB of −6 kcal/mol that represents a KI value of 10,000 nM. As results from [Fig. 1](#f0005){ref-type="fig"}, SPZ is in close contact with amino acids: Thr 25, His 41, Tyr 54, Gly 143, Cys 145, His 163, His 164, Met 165, Glu 166, Arg 188 and Gln 198 from which 6 amino acids (HIS 41, GLY 143, CYS 145, HIS 163 HIS 164 and Glu 166) are from the binding situs of the enzyme \[[@bb0105],[@bb0110]\].

SPZ forms seven distinct conformational clusters and the number of multi-member conformational clusters is 6, out of 100 runs ([Table 2](#t0010){ref-type="table"} ). The highest EFEB from 100 runs was −8.48 kcal/mol and the lowest −10.12 kcal/mol.Table 2SPZ conformational clusters, lowest binding energy from each cluster, mean binding energy of the cluster and number of conformations in the cluster.Table 2Cluster RankLowest Binding Energy kcal/molRunMean Binding Energy kcal/molNumber in Cluster1−10.1240−9.71432−9.8055−9.55293−9.7065−9.7014−9.542−9.4255−9.5499−9.4276−9.2790−9.2597−8.6364−8.586

MSO is the photoproduct with the second-highest biological activity ([Table 1](#t0005){ref-type="table"}). It is similar with SPZ and interacts with the M^pro^ of the virus in the same binding situs and has hydrogen bond interaction with amino acid residue of His 163 ([Fig. 2](#f0010){ref-type="fig"} ). SPZ highest binding energy is −8.72 kcal/mol and the lowest −9.43 kcal/mol (Table1); it forms 9 distinct conformational clusters, and the number of multi-member conformational clusters found is 7.Fig. 23D images of MSO (A) and SPZ (B) molecules with the lowest K~I~ (MSO K~I~ = 121 nM; SPZ = K~I~ 37 nM) in the run with lowest EFEB energy. Both MSO and SPZ interact with the same amino acid residues (His 163) from the M^pro^ (PDB: [6LU7](pdb:6LU7){#ir0010}) \[[@bb0075]\] and form a H-bond interaction between Oxygen atom (represented with red) and His 163 (green dotted line) amino acid residues. Except Met 165, all the amino acids residues in close contact presented in this figure in both A and B sections are amino acids from the binding pocket \[[@bb0105],[@bb0110]\]. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 2

TZ highest binding energy is −7.06 kcal/mol and the lowest is −9.02 kcal/mol (Table1). The number of distinct conformational clusters is 8 and the number of multi-member conformational clusters that were found is 3. The cluster with the largest number of population (46) had a mean binding energy of −8.22 kcal/mol. Perphenazine antipsychotic drug has the lowest binding energy (−9.06 kcal/mol) similar with TZ (Table1).

CPZ (pK~I~ 6.10) and fluphenazine (pK~I~ 6.56) exhibit a medium biological activity against SARS-CoV-2 M^pro^ (Table1). CPZ identified photoproducts had a lower biological activity than CPZ. In [Table 1](#t0005){ref-type="table"} are presented CPZ, fluphenazine and CPZ photoproducts biological activities where other results for tested phenothiazines show medium-low biological activity and are also presented. Compounds that have no biological activity or low biological activities are: *(i)* the antihistaminic drugs promethazine, thiazinam and isothipendyl; *(ii)* CPZ photoproducts PZ and P2 compound.

4. Conclusions {#s0030}
==============

Animal models infected with SARS-CoV-2 do not reproduce the same characteristic symptoms as in humans, not even in non-human primates. The animal model, that shows the clinical symptomatology of COVID-19 is represented by a transgenic mouse, that expresses human angiotensin-converting enzyme 2. The appearance of clinically observed symptomatology in the trans-genic mouse suggests that this receptor might be responsible for the access of the virus in the human cell \[[@bb0140]\].

Due to the lack of animal models, and the urgent need of treatment, molecular docking studies are suitable to speed up the process of finding compounds that present possible inhibitory activity.

Our results suggest that TZ and TZ photoproducts obtained by laser irradiation, have significant biological activity on SARS-CoV-2 M^pro^ and could be used in a potent treatment in COVID-19 disease.

According to our previous experience \[[@bb0145]\], irradiated drugs show better antibacterial activity than non-irradiated drugs and even than photoproducts tested separately. Moreover, the mixture of two obtained photoproducts has improved results compared to a single compound use.

Ergo, we recommend experimental validation of TZ, TZ photoproducts (MSO and SPZ) and irradiated TZ in interaction with SARS-CoV-2, due to the possible increased activity of a combination of such compounds. The use of the "cocktails" of irradiated TZ and its photoproducts might possibly show increased activity on SARS-CoV-2 targets.
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